PriceTargets.com logo

Shattuck Labs - STTK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.75
  • Forecasted Upside: 419.80%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.03 As of 03/24/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for STTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shattuck Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STTK

Analyst Price Target is $15.75
▲ +419.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Shattuck Labs in the last 3 months. The average price target is $15.75, with a high forecast of $28.00 and a low forecast of $9.00. The average price target represents a 419.80% upside from the last price of $3.03.

This chart shows the closing price for STTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Shattuck Labs. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2023CitigroupLower Target$13.00 ➝ $9.00Low
2/24/2023HC WainwrightReiterated RatingBuy$28.00Low
2/24/2023Needham & Company LLCLower TargetBuy$21.00 ➝ $14.00Low
2/13/2023HC WainwrightReiterated RatingBuy$28.00Low
8/31/2022BTIG ResearchInitiated CoverageBuy$12.00Low
8/12/2022Needham & Company LLCLower TargetBuy$31.00 ➝ $21.00Low
6/3/2022HC WainwrightReiterated RatingBuy$28.00Low
6/1/2022CitigroupInitiated CoverageBuy$13.00High
5/2/2022HC WainwrightInitiated CoverageBuy$28.00High
3/16/2022Needham & Company LLCLower TargetBuy$46.00 ➝ $31.00High
4/14/2021Berenberg BankInitiated CoverageBuy$47.00High
1/20/2021CitigroupBoost Target$36.00 ➝ $75.00Medium
1/11/2021Evercore ISIInitiated CoverageOutperformLow
11/3/2020Smith Barney CitigroupInitiated CoverageBuy$36.00Low
11/3/2020CowenInitiated CoverageOutperformHigh
11/3/2020Needham & Company LLCInitiated CoverageBuy$34.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Shattuck Labs logo
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $3.03
Low: $3.01
High: $3.12

50 Day Range

MA: $3.71
Low: $2.60
High: $4.72

52 Week Range

Now: $3.03
Low: $1.85
High: $5.82

Volume

8,609 shs

Average Volume

39,272 shs

Market Capitalization

$128.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Shattuck Labs?

The following sell-side analysts have issued stock ratings on Shattuck Labs in the last year: BTIG Research, Citigroup Inc., HC Wainwright, and Needham & Company LLC.
View the latest analyst ratings for STTK.

What is the current price target for Shattuck Labs?

4 Wall Street analysts have set twelve-month price targets for Shattuck Labs in the last year. Their average twelve-month price target is $15.75, suggesting a possible upside of 419.8%. HC Wainwright has the highest price target set, predicting STTK will reach $28.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $9.00 for Shattuck Labs in the next year.
View the latest price targets for STTK.

What is the current consensus analyst rating for Shattuck Labs?

Shattuck Labs currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STTK will outperform the market and that investors should add to their positions of Shattuck Labs.
View the latest ratings for STTK.

What other companies compete with Shattuck Labs?

Other companies that are similar to Shattuck Labs include Sesen Bio, ProPhase Labs, Graybug Vision, Annovis Bio and ESSA Pharma. Learn More about companies similar to Shattuck Labs.

How do I contact Shattuck Labs' investor relations team?

The company's listed phone number is 512-900-4690 and its investor relations email address is [email protected] The official website for Shattuck Labs is www.shattucklabs.com. Learn More about contacing Shattuck Labs investor relations.